{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007371","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.168930+00:00","generated_at":"2026-06-02T08:35:43.117846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition","bullets":["Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.","Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.","Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.","Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.","Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007371","json":"https://secwatch.observer/filing/0001558370-24-007371.json","markdown":"https://secwatch.observer/filing/0001558370-24-007371.md","text":"https://secwatch.observer/filing/0001558370-24-007371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/pahc-20240508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:35:43.117846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04e2cd6410c09334d8f94a83cfbfb832ea3daad3","claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended March 31, 2024 results: revenue $263.2 million, net income $8.4 million, EPS $0.21.","evidence_excerpt":"Net sales of $263.2 million, an increase of $17.6 million, or 7% - Net income of $8.4 million, a decrease of $1.6 million - Diluted earnings per share of $0.21, a decrease of $0.04","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$263.2 million"},{"label":"Net income","value":"$8.4 million"},{"label":"EPS","value":"$0.21"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"71cdb3846c539fcecb7d0ba9dd9fa78ed558c5a5","claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal year ending June 30, 2024 results: revenue $980 million to $1.020 billion, net income $7 million to $12 million, EPS $0.17 to $0.30.","evidence_excerpt":"We affirm our previously issued fiscal year 2024 guidance for the following measures: ​ – Net sales of $980 million to $1.020 billion – Adjusted EBITDA of $106 million to $112 million – Adjusted net income of $42 million to $47 million – Adjusted diluted EPS of $1.04 to $1.16 – Adjusted effective tax rate of 28% to 30% ​ We have updated our fiscal year 2024 guidance for the following measures: ​ - Net income of $7 million to $12 million - Diluted EPS of $0.17 to $0.30","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending June 30, 2024"},{"label":"Revenue","value":"$980 million to $1.020 billion"},{"label":"Net income","value":"$7 million to $12 million"},{"label":"EPS","value":"$0.17 to $0.30"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}